▶ 調査レポート

世界の持続的腎代替療法(CRRT)市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Continuous Renal Replacement Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の持続的腎代替療法(CRRT)市場2022年-2027年:成長・動向・新型コロナの影響・市場予測 / Continuous Renal Replacement Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) / MRC2203A311資料のイメージです。• レポートコード:MRC2203A311
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本市場調査レポートでは、世界の持続的腎代替療法(CRRT)市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、方法別(持続的静静脈血液透析、持続的静静脈血液ろ過、持続的静静脈血液透析ろ過、低速連続限外ろ過)分析、製品種類別(透析液・補液、使い捨て用品、システム)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の持続的腎代替療法(CRRT)市場規模:方法別(持続的静静脈血液透析、持続的静静脈血液ろ過、持続的静静脈血液透析ろ過、低速連続限外ろ過)
・世界の持続的腎代替療法(CRRT)市場規模:製品種類別(透析液・補液、使い捨て用品、システム)
・世界の持続的腎代替療法(CRRT)市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Asahi Kasei Medical Co.,Ltd、B. Braun Melsungen AG、Baxter International, Inc.、…)
・市場機会・将来傾向

The Continuous Renal Replacement Therapy Market is expected to register a CAGR of 7.2% during the forecast period. Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients with acute kidney injury, particularly patients who are hemodynamically unstable to provide renal support.

Acute kidney injury (AKI) is a sudden episode of kidney damage or kidney failure that happens within a few hours or a few days. Acute kidney injury (AKI) results in build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in the body. Acute kidney injury (AKI) can also affect other organs such as the brain, heart, and lungs. Acute kidney injury generally common in patients who are in the hospital, in intensive care units, and especially in older adults. According to the International Society of Nephrology, every year approximately 13.3 million cases of acute kidney injury (AKI) globally, particularly high in emerging countries, where annual incidence is estimated to be 11.3 million. Increasing geriatric population and incidences of acute kidney injury, technological advancements in continuous renal replacement therapy are the key driving factors in continuous renal replacement therapy market.

Key Market Trends

Continuous Venovenous Haemofiltration Segment is Expected to Hold a Major Market Share in the Continuous Renal Replacement Therapy Market

  • Continuous Veno-Venous Hemofiltration (CVVH) is a temporary treatment for patients suffering with acute renal failure who are unable to tolerate hemodialysis and are unstable. With Continuous Veno-Venous Hemofiltration (CVVH), a dialysis catheter is placed in one of the main veins of the body.
  • According to International Society of Nephrology, Acute kidney injury (AKI) is experienced by 13.3 million patients every year globally and between 5.3 and 10.5 million people require dialysis or transplantation.
  • Continuous venovenous haemofiltration segment hold a significant market share in the continuous renal replacement therapy market and is anticipated to show similar trend over the forecast period due to high acceptance of continuous venovenous haemofiltration by nephrologists, because it is more feasible than the other modes and also incurs less complications than other modes of continuous renal replacement therapy.
  • Increasing geriatric population and incidences of acute kidney injury and technological advancements are the key driving factors in the continuous venovenous haemofiltration segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global continuous renal replacement therapy market due to rise in geriatric population and increasing incidences of acute kidney injury in this region. According to Centers for Disease Control and Prevention (CDC), approximately 30 million people or 15% of United States adults are estimated to have chronic kidney disease (CKD). chronic kidney disease (CKD) is estimated to be more common in women (16%) than in men (13%). Furthermore, high adoption rates of new technologies in continuous renal replacement therapy and the presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Continuous Renal Replacement Therapy Market is moderately fragmented competitive and consists of several major players. In terms of market share, few of the major manufacturers are currently dominating the capital equipment segment of the market. Some of the companies which are currently dominating the market are Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG, Baxter International, Inc, Fresenius Medical Care AG & Co. KgaA, Infomed SA, Medica SpA, Medical Components, Inc, Medites Pharma Spol. S.R.O, Medtronic PLC, and Toray Medical Co., Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Aging Population Increases Incidences of Acute Kidney Injury
4.2.2 Technological Advancements in Continuous Renal Replacement Therapy
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 High Cost Associated Continuous Renal Replacement Therapy
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Mode
5.1.1 Continuous Venovenous Hemodialysis
5.1.2 Continuous Venovenous Hemofiltration
5.1.3 Continuous Venovenous Hemodiafiltration
5.1.4 Slow Continuous Ultrafiltration
5.2 By Product Type
5.2.1 Dialysate and Replacement Fluids
5.2.2 Disposables
5.2.3 Systems
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Asahi Kasei Medical Co., Ltd
6.1.2 B. Braun Melsungen AG
6.1.3 Baxter International, Inc.
6.1.4 Fresenius Medical Care AG & Co. KgaA
6.1.5 Infomed SA
6.1.6 Medica SpA
6.1.7 Medical Components, Inc
6.1.8 Medites Pharma Spol. S.R.O
6.1.9 Medtronic PLC
6.1.10 Toray Medical Co., Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS